Johnson-Johnson

CONSUMER SEGMENT (2) SKIN CARE US Intl WW BABY CARE US Intl WW ORAL CARE US Intl WW OTC/NUTRITIONALS US Intl WW WOMEN'S HEALTH US Intl WW WOUND CARE / OTHER US Intl WW TOTAL CONSUMER US Intl

		THIRD QUAR	TER				NINE MONTH	S	
2009		-				% Change			
	2008	Reported O	oerational (1)	Currency	2009	<u>2008</u>	Reported Op	erational (1)	Currenc
370	358	3.4%	3.4%		1,204	1,119	7.6%	7.6%	
472	500	-5.6%	-0.1%	-5.5%	1,313	1,119	-7.4%	3.0%	-10.4%
842	858	-1.9%	1.3%	-3.2%	2,517	2,537	-0.8%	5.0%	-5.8%
						,			
102	114	-10.5%	-10.5%	-	308	340	-9.4%	-9.4%	
442	472	-6.4%	-0.7%	-5.7%	1,233	1,351	-8.7%	0.7%	-9.4%
544	586	-7.2%	-2.6%	-4.6%	1,541	1,691	-8.9%	-1.4%	-7.5%
187	204	-8.3%	-8.3%	-	549	588	-6.6%	-6.6%	
223	230	-3.0%	4.8%	-7.8%	612	640	-4.4%	8.3%	-12.79
410	434	-5.5%	-1.4%	-4.1%	1,161	1,228	-5.5%	1.1%	-6.6%
		5.00/	5.00/				7.00/	7.00/	
732	778	-5.9%	-5.9%	7.00/	2,137	2,299	-7.0%	-7.0%	40.40
666	661	0.8%	8.0%	-7.2%	1,919	2,139	-10.3%	1.8%	-12.19
1,398	1,439	-2.8%	0.5%	-3.3%	4,056	4,438	-8.6%	-2.8%	-5.8%
142	164	-13.4%	-13.4%	-	443	470	-5.7%	-5.7%	
360	346	4.0%	11.7%	-7.7%	963	1,005	-4.2%	7.2%	-11.49
502	510	-1.6%	3.6%	-5.2%	1,406	1,475	-4.7%	3.1%	-7.8%
158	151	4.6%	4.6%	_	484	466	3.9%	3.9%	
135	121	11.6%	18.0%	-6.4%	389	364	6.9%	18.8%	-11.9
293	272	7.7%	10.5%	-2.8%	873	830	5.2%	10.5%	-5.3%
1,691	1.769	-4.4%	-4.4%	_	5,125	5.282	-3.0%	-3.0%	
2.298	2.330	-4.4% -1.4%	-4.4% 5.2%	-6.6%	6,429	5,262 6,917	-3.0% -7.1%	-3.0% 4.1%	-11.29
3,989	4,099	-1.4% -2.7%	5.2% 1.1%	-3.8%	11,554	12,199	-7.1% -5.3%	1.0%	-6.39

^{*} See footnotes on page 3

ww

			TUIDD QUAD		PRIOR PERIOD (\$MM)					
		THIRD QUARTER % Change			NINE MONTHS % Change					
	2000	2000	Reported Operational (1)		C	_ 2000 2000		Reported Operational (1) Currency		
	2009	2008	Reported O	perational (1)	Currency	<u>2009</u>	<u>2008</u>	Reported O	perational (1)	Currency
PHARMACEUTICAL SEGMENT (2)										
ACIPHEX/PARIET										
US	131	130	0.8%	0.8%	-	397	399	-0.5%	-0.5%	-
Intl	130	152	-14.5%	-9.0%	-5.5%	387	485	-20.2%	-9.3%	-10.9%
WW CONCERTA	261	282	-7.4%	-4.4%	-3.0%	784	884	-11.3%	-5.3%	-6.0%
US US	205	190	7.9%	7.9%	_	707	622	13.7%	13.7%	_
Intl	79	208	-62.0%	-59.2%	-2.8%	238	345	-31.0%	-20.8%	-10.2%
WW	284	398	-28.6%	-27.2%	-1.4%	945	967	-2.3%	1.3%	-3.6%
DURAGESIC/FENTANYL TRANSDERMAL US	20	E4	20.69/	20.00/		462	400	40.40/	40.40/	
Intl	38 168	54 205	-29.6% -18.0%	-29.6% -15.2%	-2.8%	163 492	199 565	-18.1% -12.9%	-18.1% -4.3%	-8.6%
WW	206	259	-20.5%	-18.3%	-2.2%	655	764	-14.3%	-8.0%	-6.3%
LEVAQUIN/FLOXIN										
US	294	313	-6.1%	-6.1%	-	1,045	1,117	-6.4%	-6.4%	
Intl WW	17 311	20 333	-15.0% -6.6%	0.3% -5.7%	-15.3% -0.9%	53 1,098	63 1,180	-15.9% -6.9%	1.4% -6.0%	-17.3% -0.9%
PROCRIT/EPREX	311	555	0.070	3.7 70	0.570	1,030	1,100	0.570	0.070	0.570
US	299	334	-10.5%	-10.5%	-	950	1,014	-6.3%	-6.3%	-
Intl	243	285	-14.7%	-9.6%	-5.1%	719	886	-18.8%	-9.0%	-9.8%
WW	542	619	-12.4%	-10.0%	-2.4%	1,669	1,900	-12.2%	-7.6%	-4.6%
RAZADYNE/REMINYL US		24	00.00/	00.00/		20	400	7F C0/	75.00/	
Intl	1 96	31 107	-96.8% -10.3%	-96.8% -3.8%	-6.5%	30 275	123 316	-75.6% -13.0%	-75.6% -1.2%	-11.8%
WW	97	138	-29.7%	-24.7%	-5.0%	305	439	-30.5%	-22.0%	-8.5%
REMICADE										
US	822	778	5.7%	5.7%	-	2,330	2,138	9.0%	9.0%	-
US Exports (4) Intl	208 6	198 2	5.1% 200.0%	5.1% 198.7%	1.3%	821 15	718 6	14.3% 150.0%	14.3% 145.8%	4.2%
WW	1,036	978	5.9%	5.9%	1.3 /6	3,166	2,862	10.6%	10.6%	4.2 /0
RISPERDAL/RISPERIDONE	,						,			
US	35	122	-71.3%	-71.3%		223	1,196	-81.4%	-81.4%	
Intl WW	157 192	198 320	-20.7% -40.0%	-21.4% -40.4%	0.7% 0.4%	483 706	645 1,841	-25.1% -61.7%	-21.3% -60.4%	-3.8% -1.3%
RISPERDAL CONSTA	192	320	-40.076	-40.476	0.476	700	1,041	-01.7 /6	-00.4 /0	-1.370
US	129	118	9.3%	9.3%	_	386	339	13.9%	13.9%	_
Inti	224	220	1.8%	10.2%	-8.4%	640	651	-1.7%	12.6%	-14.3%
WW	353	338	4.4%	9.9%	-5.5%	1,026	990	3.6%	13.0%	-9.4%
TOPAMAX	70	coc	00.40/	00.40/		640	4.674	C4 C0/	C4 C0/	
US Intl	72 103	606 122	-88.1% -15.6%	-88.1% -7.9%	- -7.7%	642 317	1,674 377	-61.6% -15.9%	-61.6% -3.5%	- -12.4%
WW	175	728	-76.0%	-74.7%	-1.3%	959	2,051	-53.2%	-50.9%	-2.3%
VELCADE										
US	-	1	-100.0%	-100.0%	-	-	4	-100.0%	-100.0%	-
Intl	231	189	22.2%	31.1%	-8.9%	652	575	13.4% 12.6%	26.7%	-13.3%
WW	231	190	21.6%	30.5%	-8.9%	652	579	12.6%	25.8%	-13.2%
<u>OTHER</u> US	623	663	-6.0%	-6.0%	-	2,009	1,858	8.1%	8.1%	-
Intl	938	867	8.2%	13.6%	-5.4%	2,553	2,567	-0.5%	9.2%	-9.7%
WW	1,561	1,530	2.0%	5.1%	-3.1%	4,562	4,425	3.1%	8.8%	-5.7%
TOTAL PHARMACEUTICAL			40.00/	40.00/			44.404	4.4.00/	4.4.00/	
US Intl	2,857 2,392	3,538 2,575	-19.2% -7.1%	-19.2% -1.9%	- -5.2%	9,703 6,824	11,401 7,481	-14.9% -8.8%	-14.9% 1.4%	-10.2%
WW	5,249	6,113	-14.1%	-11.9%	-2.2%	16,527	18,882	-12.5%	-8.5%	-4.0%
		0,		111070		10,021	.0,002	.2.070	0.070	
MAJOR NEW PHARM PRODUCTS (5)										
<u>PREZISTA</u> US	78	34	129.4%	129.4%	_	215	109	97.2%	97.2%	_
Intl	73	45	62.2%	77.0%	-14.8%	198	132	50.0%	70.0%	-20.0%
WW	151	79	91.1%	99.5%	-8.4%	413	241	71.4%	82.3%	-10.9%
<u>INVEGA</u>										
US	61	73 46	-16.4%	-16.4%	- 17 F0/	194	192	1.0%	1.0%	
Intl WW	36 97	16 89	125.0% 9.0%	142.5% 12.3%	-17.5% -3.3%	93 287	39 231	138.5% 24.2%	168.1% 29.2%	-29.6% -5.0%
	J.	00	3.070	12.070	0.070	20,	201	∠ T.∠ /U	20.270	0.070
* See footnotes on page 3	-					-				

^{*} See footnotes on page 3

	THIRD QUARTER					NINE MONTHS					
			% Change					% Change			
	2009	2008	Reported Operational (1)		Currency	2009	2008	Reported Or	perational (1)	Currency	
					<u></u>			110001100		<u> </u>	
MEDICAL DEVICES AND DIAG (2) (3)											
CORDIS (6)											
US	233	259	-10.0%	-10.0%	-	731	929	-21.3%	-21.3%	-	
Intl	407	431	-5.6%	-4.6%	-1.0%	1,251	1,375	-9.0%	-3.9%	-5.1%	
WW	640	690	-7.2%	-6.6%	-0.6%	1,982	2,304	-14.0%	-10.9%	-3.1%	
DEPUY											
US	740	698	6.0%	6.0%		2,268	2,129	6.5%	6.5%		
Intl	544	533	2.1%	7.6%	-5.5%	1,631	1,717	-5.0%	6.8%	-11.8%	
WW	1,284	1,231	4.3%	6.7%	-2.4%	3,899	3,846	1.4%	6.7%	-5.3%	
DIABETES CARE											
US	332	349	-4.9%	-4.9%		908	990	-8.3%	-8.3%		
= =	302	349 318	-4.9% -5.0%	-4.9%	4.00/		966	-0.3% -9.2%	-o.3% 0.2%	0.40/	
Intl WW	634	667			-4.6%	877				-9.4%	
VVVV	634	007	-4.9%	-2.7%	-2.2%	1,785	1,956	-8.7%	-4.1%	-4.6%	
ETHICON											
US	439	372	18.0%	18.0%	_	1,296	1,087	19.2%	19.2%	_	
Intl	580	585	-0.9%	3.8%	-4.7%	1,717	1,835	-6.4%	3.6%	-10.0%	
WW	1,019	957	6.5%	9.4%	-2.9%	3,013	2,922	3.1%	9.3%	-6.2%	
	1,010	00.	0.070	0.170	2.070	0,010	_,0	0.170	0.070	0.270	
ETHICON ENDO-SURGERY											
US	499	473	5.5%	5.5%	-	1,442	1,386	4.0%	4.0%	-	
Intl	607	569	6.7%	10.9%	-4.2%	1,794	1,783	0.6%	10.6%	-10.0%	
WW	1,106	1,042	6.1%	8.4%	-2.3%	3,236	3,169	2.1%	7.7%	-5.6%	
ORTHO-CLINICAL DIAGNOSTICS											
US	285	261	9.2%	9.2%	-	846	749	13.0%	13.0%	-	
Intl	216	209	3.3%	7.0%	-3.7%	616	640	-3.8%	4.8%	-8.6%	
WW	501	470	6.6%	8.2%	-1.6%	1,462	1,389	5.3%	9.3%	-4.0%	
VICION CARE											
VISION CARE US	220	236	0.8%	0.8%		702	600	2.0%	2.00/		
= =	238				4 40/	703	689		2.0%	- 00/	
Intl	421	416	1.2%	-0.2%	1.4%	1,185	1,209	-2.0%	0.3%	-2.3%	
WW	659	652	1.1%	0.2%	0.9%	1,888	1,898	-0.5%	0.9%	-1.4%	
TOTAL MEDICAL DEVICES AND DIAG											
US	2,766	2,648	4.5%	4.5%	_	8,194	7,959	3.0%	3.0%	-	
Intl	3,077	3,061	0.5%	3.8%	-3.3%	9,071	9,525	-4.8%	3.7%	-8.5%	
WW	5,843	5,709	2.3%	4.1%	-1.8%	17,265	17,484	-1.3%	3.3%	-4.6%	
	1	•				11 1	•				

REPORTED SALES vs. PRIOR PERIOD (\$MM)

 $^{^{\}left(1\right) }$ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Prior year amounts have been reclassified to conform with current presentation

⁽⁴⁾ For external purposes, reported as U.S. sales

⁽⁵⁾ Included in Other

⁽⁶⁾ Includes sales of Drug-Eluting Stents for Q3 2009 of \$53, \$158 and \$211MM Domestic, International and Worldwide respectively Includes sales of Drug-Eluting Stents for Q3 2008 of \$97, \$192 and \$289MM Domestic, International and Worldwide respectively Includes sales of Drug-Eluting Stents for September YTD 2009 of \$189, \$507 and \$696MM Domestic, International and Worldwide respectively Includes sales of Drug-Eluting Stents for September YTD 2008 of \$433, \$650 and \$1,083MM Domestic, International and Worldwide respectively